Stemline Therapeutics Inc. (NASDAQ:STML)’s share price shot up 1.8% during mid-day trading on Wednesday . The company traded as high as $7.48 and last traded at $7.36, with a volume of 58,740 shares. The stock had previously closed at $7.23.

A number of research firms have recently issued reports on STML. Zacks Investment Research downgraded Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Wedbush restated an “outperform” rating and issued a $16.00 price target on shares of Stemline Therapeutics in a research note on Tuesday, June 7th. Jefferies Group restated a “buy” rating on shares of Stemline Therapeutics in a research note on Friday, August 5th. Finally, Roth Capital restated a “buy” rating and issued a $32.00 price target on shares of Stemline Therapeutics in a research note on Thursday, June 9th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $19.56.

The company’s market cap is $130.48 million. The firm’s 50-day moving average is $7.19 and its 200-day moving average is $6.03.

Stemline Therapeutics (NASDAQ:STML) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. Analysts anticipate that Stemline Therapeutics Inc. will post ($2.11) EPS for the current fiscal year.

An institutional investor recently raised its position in Stemline Therapeutics stock. Royce & Associates LLC raised its position in Stemline Therapeutics Inc. (NASDAQ:STML) by 318.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 159,179 shares of the biopharmaceutical company’s stock after buying an additional 121,179 shares during the period. Royce & Associates LLC owned approximately 0.91% of Stemline Therapeutics worth $1,004,000 as of its most recent SEC filing.

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.